NCT02845609 (SA-thrombo) is a Phase 2 clinical trial of Sialic Acid-Extended Release in Thrombocytopenia, sponsored by Hadassah Medical Organization.

Who is sponsoring NCT02845609?

NCT02845609 is sponsored by Hadassah Medical Organization.

What drugs are being tested in NCT02845609?

Interventions in NCT02845609: Sialic Acid-Extended Release.

What condition does NCT02845609 study?

NCT02845609 studies Thrombocytopenia.

Is NCT02845609 still recruiting?

NCT02845609 is currently completed. Last updated 29 January 2018.

Last reviewed 2018-01-29 · How we verify

NCT02845609: SA-thrombo

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase 2 Study to Evaluate the Efficacy of Sialic Acid-Extended Release (SA-ER) Tablets in Patients With GNE Related Thrombocytopenia

Completed Phase 2 Last updated 29 January 2018

What this trial tests

Phase 2 trial testing Sialic Acid-Extended Release in Thrombocytopenia in 5 participants. Completed in 1 September 2017.

Timeline

1 September 2016

Primary endpoint
1 September 2017

1 September 2017

Quick facts

Lead sponsor	Hadassah Medical Organization
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	5
Start date	1 September 2016
Primary completion	1 September 2017
Estimated completion	1 September 2017

Drugs / interventions tested

Sialic Acid-Extended Release — full drug profile →

Conditions studied

Thrombocytopenia — all drugs for Thrombocytopenia →

Sponsor

Hadassah Medical Organization — full company profile →

Who can join

Adults 18 to 45, any sex, with Thrombocytopenia. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Increase in platelet count from baseline
Time frame: 3 month

Sponsor's own description

Sialic Acid-Extended Release (SA-ER, aceneuramic acid, UX001) is an extended release formulation of sialic acid (SA, also known as N-acetylneuraminic acid or NANA). The SA-ER is currently studied as a substrate replacement therapy for patients with GNE myopathy. The investigators plan to study the SA-ER compound in a cohort of five patients with GNE-related thrombocytopenia.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Biosynthetic and genetic pathways related to sialic acid metabolism.
Huang S, van de Ven EGP, Tee T, Lefeber DJ. · · 2026 · PMID 41655697 · DOI 10.1016/j.jbc.2026.111262

Verify or expand the search:

Other recruiting trials for Thrombocytopenia

Currently open trials in the same condition.

NCT07441720 — Safety and Efficacy of Umbilical Cord Blood Therapy for Cancer Therapy-Induced Thrombocytopenia (CTIT) · Phase 2 · recruiting
NCT07442513 — Comparison of Etamsylate Versus Placebo to Prevent Bleeding in HSCT · Phase 3 · recruiting
NCT07257809 — Herombopag Treated T-DM1 Induced Platelet Reduction · Phase 2 · recruiting
NCT06676904 — Neonatal Platelet Transfusion Threshold Trial · NA · recruiting
NCT06886516 — Apixaban in Thrombocytopenia · EARLY_PHASE1 · recruiting

Other Hadassah Medical Organization trials

Trials by the same sponsor.

NCT07430358 — Obstetric Risk Assessment & Cesarean-delivery in Labor Estimation Using Artificial Intelligence · NA · not yet recruiting
NCT07429019 — Intraoperative Bupivacaine Injection to Reduce Acute and Chronic Pain After TVT/TVT-O Surgery. Randomized Double-Blind T · NA · not yet recruiting
NCT07393568 — The Influence of Patient Use of Artificial Intelligence on Doctor-Patient Interaction and Clinical Outcomes in Endometri · not yet recruiting
NCT07333430 — Study of Naive HBI0101 CAR-T Therapy in Relapsed/Refractory Multiple Myeloma · Phase 1 · recruiting
NCT06762730 — Zoledronic Acid for the Prevention of TDF-sparing ART-induced Bone Mass Density Loss in Treatment-naive HIV Positive Ind · Phase 4 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02845609 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hadassah Medical Organization
Last refreshed: 29 January 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02845609.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing